Today: Heartland Advisors Inc. Buys 100,000 Shares of Harvard Bioscience Inc. (HBIO)

Today: Heartland Advisors Inc. Buys 100,000 Shares of Harvard Bioscience Inc. (HBIO)

Heartland Advisors Inc. boosted its position in Harvard Bioscience Inc. (NASDAQ:HBIO) by 4.5% during the third quarter, Holdings Channel reports. The fund owned 2,300,000 shares of the company’s stock after buying an additional 100,000 shares during the period. Heartland Advisors Inc. owned approximately 0.07% of Harvard Bioscience worth $6,256,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Foundry Partners LLC boosted its stake in shares of Harvard Bioscience by 0.3% in the second quarter. Foundry Partners LLC now owns 505,925 shares of the company’s stock worth $1,447,000 after buying an additional 1,475 shares during the period. First Manhattan Co. bought a new stake in shares of Harvard Bioscience during the second quarter worth $125,000. Acadian Asset Management LLC boosted its stake in shares of Harvard Bioscience by 3.1% in the second quarter. Acadian Asset Management LLC now owns 729,779 shares of the company’s stock worth $2,088,000 after buying an additional 21,961 shares during the period. ClariVest Asset Management LLC boosted its stake in shares of Harvard Bioscience by 3.9% in the second quarter. ClariVest Asset Management LLC now owns 199,831 shares of the company’s stock worth $571,000 after buying an additional 7,500 shares during the period. Finally, Cadence Capital Management LLC boosted its stake in shares of Harvard Bioscience by 10.0% in the second quarter. Cadence Capital Management LLC now owns 273,812 shares of the company’s stock worth $783,000 after buying an additional 24,926 shares during the period. 64.80% of the stock is currently owned by institutional investors and hedge funds.

Harvard Bioscience Inc. (NASDAQ:HBIO) traded down 3.77% during midday trading on Monday, reaching $2.55. The company’s stock had a trading volume of 12,030 shares. The firm’s market capitalization is $87.65 million. Harvard Bioscience Inc. has a 1-year low of $2.25 and a 1-year high of $3.90. The stock’s 50-day moving average price is $2.51 and its 200 day moving average price is $2.86.

HBIO has been the subject of a number of analyst reports. Zacks Investment Research cut Harvard Bioscience from a “hold” rating to a “sell” rating in a research note on Tuesday, August 2nd. Singular Research initiated coverage on Harvard Bioscience in a research note on Thursday, November 17th. They set a “buy” rating and a $5.50 price objective for the company. Finally, Benchmark Co. set a $6.00 price objective on Harvard Bioscience and gave the stock a “buy” rating in a research note on Monday, November 21st.

In other news, CFO Robert E. Gagnon acquired 25,000 shares of the company’s stock in a transaction dated Thursday, November 3rd. The stock was acquired at an average cost of $2.34 per share, with a total value of $58,500.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Jeffrey Duchemin acquired 15,000 shares of the company’s stock in a transaction dated Thursday, November 3rd. The stock was purchased at an average cost of $2.42 per share, with a total value of $36,300.00. The disclosure for this purchase can be found here. 8.80% of the stock is owned by insiders.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company’s products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors.

Related posts

Leave a Comment